Results 241 to 250 of about 80,532 (301)

CDH17-targeting CAR-NK cells synergize with CD47 blockade for potent suppression of gastrointestinal cancers. [PDF]

open access: yesActa Pharm Sin B
Zheng L   +16 more
europepmc   +1 more source

Clinical characteristics, treatment response, and survival outcomes in melanoma patients with cavity carcinomatosis: A retrospective analysis

open access: yesInternational Journal of Cancer, Volume 158, Issue 9, Page 2418-2428, 1 May 2026.
What's new? Cavity carcinomatosis, a late manifestation of cancer, fuels tumor formation throughout a large area, most commonly the peritoneal and pleural cavities. The condition also can lead to resistance to otherwise effective treatment strategies.
Zhongqiao Lin   +6 more
wiley   +1 more source

Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma. [PDF]

open access: yesJ Transl Med
Lin X   +15 more
europepmc   +1 more source

CAR‐T Cells: Current Status, Challenges, and Future Prospects

open access: yesMedComm, Volume 7, Issue 5, May 2026.
This graphical abstract outlines the current status, challenges, and future prospects of CAR‐T cells. The biological basis of CAR‐T cell therapy is the elegant redirection of adaptive immunity. Its initial successes have exposed a landscape of multifaceted challenges.
Aya Sedky Adly   +6 more
wiley   +1 more source

Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications

open access: yesMedComm, Volume 7, Issue 5, May 2026.
Mutant isocitrate dehydrogenase affects multiple cancer types. Alterations in IDH1 and IDH2 result in abnormal enzyme activity, leading to the overproduction of D‐2‐hydroxyglutarate (D‐2HG). This metabolite disrupts cellular metabolism and epigenetic regulation, driving cancer initiation, progression, and metastasis.
Yuhan Fang   +6 more
wiley   +1 more source

Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy

open access: yesMedComm, Volume 7, Issue 5, May 2026.
Immunotherapies dependent on classical MHC‐I molecules face significant challenges, including extreme polymorphism and frequent downregulation in pathological conditions. This review discusses how nonclassical MHC‐I molecules (HLA‐E, HLA‐F, HLA‐G, CD1, MR1) may potentially circumvent these limitations through restricted genetic diversity, stable ...
Wanlin He, Andrew J. McMichael
wiley   +1 more source

Corrigendum: Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer. [PDF]

open access: yesFront Immunol
Kutle I   +16 more
europepmc   +1 more source

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients – PART 1: Risk Factors, Clinical Impact and Immune Response

open access: yesReviews in Medical Virology, Volume 36, Issue 3, May 2026.
ABSTRACT Human cytomegalovirus (HCMV) is one of the most important opportunistic pathogens in immunocompromised individuals, including allogeneic haematopoietic stem cell transplant (allo‐HSCT) recipients. In allo‐HSCT, HCMV seropositivity of the recipient and donor is associated with inferior survival outcomes, and post‐transplant HCMV reactivation is
Danya Kaplan   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy